



IFIN

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and  
Analogs and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

**Information Disclosure Statement Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey S. Lundgren  
Agent for Applicants  
Registration No. 51,978

Date: Aug. 20, 2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

1483.0340003/JMC/JSL

APPLICATION NO.

10/772,445

FIRST NAMED INVENTOR

Upasani et al.

FILING DATE

February 6, 2004

ART UNIT

1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,748,331	06/24/1973	Cooke et al.			05/06/1971
	AB1	3,963,717	06/15/1976	Cooke et al.			03/10/1975
	AC1	5,284,957	02/08/1994	Huff			09/03/1992
	AD1	5,514,680	05/07/1996	Weber et al.			11/05/1993
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 94/13275	06/23/1993	WIPO			Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Anderson, B.A. et al., "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," <i>J. Am. Chem. Soc.</i> 117:12358-12359, American Chemical Society (1995)
	AS	1	Buchan, A.M. et al., "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia," <i>Neuroreport</i> 2:473-476, Lippincott, Williams & Wilkins (1991)
	AT	1	Buchan, A.M. et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl. I</i> 24:I-148-I-154, Lippincott, Williams & Wilkins (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	2	Choi, D.W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," <i>J. Neurosci</i> 7:357-368, Society for Neuroscience (1987)
AS	2	Coombs, R.V. et al., "Synthesis and Antiinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and Quinazolinethiones," <i>J. Med. Chem.</i> 16:1237-1245, American Chemical Society (1973)
AT	2	Copani, A. et al., "Nootropic Drugs Positively Modulate $\gamma$ -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid-Sensitive Glutamate Receptors in Neuronal Cultures," <i>J. Neurochem.</i> 58:1199-1204, The International Society for Neurochemistry (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	<u>3</u>	De Sarro, G. et al., "GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice," <i>Eur. J. Pharmacol.</i> 294:411-422, Elsevier Science (1995)
AS	<u>3</u>	Fetter, J. et al., "Electron Deficient Heteroaromatic Ammonioamides-XVI," <i>Tetrahedron</i> 34:2557-2563, Pergamon Press (1978)
AT	<u>3</u>	Graham, S.H. et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," <i>J. Pharm. Exp. Ther.</i> 276:1-4, American Society for Pharmacology and Experimental Therapeutics (1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	4	Haider, N., "Convenient Synthesis of Cycloalkene-Fused Phthalazinones," <i>Heterocycles</i> 41:2519-2525, Sendai Institute of Heterocyclic Chemistry (1995)
AS	4	Houlihan, W.J. et al., "Antiinflammatory Properties of 8-Aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones," <i>J. Med. Chem.</i> 25:1110-1113, American Chemical Society (1982)
AT	4	Hunter, J.C. and L. Singh, "Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat," <i>Neurosci Lett.</i> 174:217-221, Elsevier Scientific Publishers (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	5	Ikeda, A. et al., "Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan," <i>Movement Disorders</i> 11:691-700, Raven Press (1996)
AS	5	Iwasaki, Y. et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurosci.</i> 134:21-25, Society for Neuroscience (1995)
AT	5	Jones, B.J. et al., "The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist," <i>Br. J. Pharmacol.</i> 93:985-993, Macmillan Journals Ltd. (1988)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 1483.0340003/JMC/JSL		APPLICATION NO. 10/772,445	
		FIRST NAMED INVENTOR Upasani et al.			
		FILING DATE February 6, 2004		ART UNIT 1615	

<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR	6	Keana, J.F.W. et al., "Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors," <i>J. Med. Chem.</i> 38:4367-4379, American Chemical Society (1995)				
	AS	6	Larson, J. et al., "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats," <i>Brain Res.</i> 738:353-356, Elsevier/North-Holland Biomedical Press (1996)				
	AT	6	Le Peillet, E. et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571:115-120, Elsevier/North-Holland Biomedical Press (1992)				

EXAMINER	DATE CONSIDERED
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	7	Lipton, S. and P.A. Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders," <i>N. Engl. J. Med.</i> 330:613-622, Massachusetts Medical Society (1994)
AS	7	McDonald, J.W. et al., "Physiological and pathophysiological roles of excitatory amino acids during central nervous system development," <i>Brain Res. Rev.</i> 15:41-70, Elsevier Science (1990)
AT	7	Pelletier, J.C. et al., "Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor," <i>J. Med. Chem.</i> 39:343-346, American Chemical Society (1996)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	8	Sang, C.N. et al., "Analgesic Effects of AMPA/Kainate Antagonist LY293558 in Human: Reduction of Capsaicin-Evoked Allodynia and Hyperalgesia But Not Pain Sensations In Normal Skin," <i>Soc. Neurosci</i> 23:1015, Abstract No. 401.14, Society of Neuroscience (October 1997)
AS	8	Schoepp, D. et al., "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors," <i>Trends Pharm Sci</i> 11:508-515, Elsevier in Association with the International Union of Pharmacology (1990)
AT	8	Sheardown, M.J. et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxalin: A Neuroprotectant for Cerebral Ischemia," <i>Science</i> 247:571-574, American Association for the Advancement of Science (1990)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	9	Sheardown, M.J. et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharmacol. 236:347-353, Elsevier Science (1993)
AS	9	Staubli, U. et al., "Facilitation of glutamate receptors enhances memory," Proc. Natl. Acad. Sci. USA 91:777-781, National Academy of Sciences (1994)
AT	9	Thomas, R.J., "Excitatory Amino Acids in Health and Disease," J. Am. Geriatr. Soc. 43:1279-1289, Blackwell Science (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
		FIRST NAMED INVENTOR Upasani et al.	FILING DATE February 6, 2004
		ART UNIT 1615	

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR	10	Woodward, R.M. et al., "In Vitro Pharmacology of ACEA-1021 and ACEA-1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-aspartate Receptor Glycine Sites," <i>Mol. Pharmacol.</i> 47:568-581, American Society for Pharmacology and Experimental Therapeutics (1995)
AS	10	Wrathall, J.R. et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-Methyl-D-Aspartate receptors," <i>Exp. Neurology</i> 137:119-126, Academic Press (1996)
AT		

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gen G. Durkin  
Michele A. Cimbara  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes

Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhuillier  
Rae Lynn P. Guest  
George S. Bardmessner  
Daniel A. Klein\*  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller\*  
LuAnne M. DeSantis  
Ann E. Summerfield  
Ant W. Ledford\*  
Helene C. Carlson  
Timothy A. Doyle\*  
Gaby L. Longsworth  
Lori A. Gordon\*  
Nicole D. Dretar\*

Ted J. Ebersole  
Jyoti C. Iyer\*  
Laura A. Vogel  
**Registered Patent Agents•**  
Karen R. Markowitz  
Nancy J. Leith  
Matthew J. Dowd  
Aaron L. Schwartz  
Katrina Yujian Pei Quach  
Bryan L. Shelton  
Robert A. Schwartzman  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Michelle K. Holoubek  
Robert H. DeSelms  
Simon J. Elliott

Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Michael G. Penn  
Christopher J. Walsh

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith  
Marvin C. Guthrie

\*Admitted only in Maryland  
+Admitted only in Virginia  
•Practice Limited to  
Federal Agencies

August 20, 2004

**WRITER'S DIRECT NUMBER:**  
(202) 772-8787  
**INTERNET ADDRESS:**  
LUNDGREN@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1615**

Re: U.S. Utility Patent Application  
Application No. 10/772,445; Filed: February 6, 2004  
For: **Substituted Quinazolines and Analogs and the Use Thereof**  
Inventors: Upasani *et al.*  
Our Ref: 1483.0340003/JMC/JSL

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 citing documents on Information Disclosure Statement (AA1-AD1, AL1, AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10, AS10);
3. First Supplemental Information Disclosure Statement;
4. Form PTO-1449 citing documents on First Supplemental Form PTO-1449 citing documents (AE1-AH1, AM1-AP1, AT10, AL2);
5. Second Supplemental Information Disclosure Statement;
6. Form PTO-1449 citing documents on Second Supplemental Form PTO-1449 citing documents (AM2, and AR11-AT11); and
7. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
August 20, 2004  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Jeffrey S. Lundgren  
Agent for Applicants  
Registration No. 51,978

JSL/asl  
Enclosures

301903v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and  
Analogues and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

**First Supplemental Information Disclosure Statement**

**Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this First Supplemental Information Disclosure Statement is a continuation of Applicants' Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of documents AE1 to AH1, AM1 to AL2, and AT10 were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AN1 cited on Form PTO 1449:

Document AN1 is in a foreign language. An English language abstract of document AN1 is attached as document AT10.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey S. Lundgren  
Agent for Applicants  
Registration No. 51,978

Date: Aug 20, 2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449 <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>			ATTY. DOCKET NO. 1483.0340003/JMC/JSL		APPLICATION NO. 10/772,445		
			FIRST NAMED INVENTOR Upasani et al.				
			FILING DATE February 6, 2004		ART UNIT 1516		
			<b>U.S. PATENT DOCUMENTS</b>				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE1	3,759,920	09/18/1973	Linder et al.			06/24/1971
	AF1	3,856,960	12/24/1974	Cooke et al.			04/13/1973
	AG1	4,224,328	09/23/1980	Takesue			04/11/1979
	AH1	5,650,410	07/22/1997	Sohda et al.			04/17/1995
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM1	DE 2 058 722	06/09/1971	Germany			X Yes No
	AN1	DE 2 307 808	08/30/1973	Germany			Yes X No
	AO1	GB 1341401	12/19/1993	Great Britain			Yes No
	AP1	EP 0 567 107 A1	10/27/1993	Europe			Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR						
	AS						
	AT	10	Dialog File 351, Accession No. 1973-41080U/197329, Derwent WPI English language abstract for DE 2 307 808 (Document AN1)				
EXAMINER					DATE CONSIDERED		
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449		FIRST NAMED INVENTOR Upasani et al.	
<u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		FILING DATE February 6, 2004	ART UNIT 1516

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 634 169 A1	01/18/1995	Europe			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Copy*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and  
Analogs and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

**Second Supplemental Information Disclosure Statement**

**Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this Second Supplemental Information Disclosure Statement is a continuation of Applicants' First Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 10/219,755, filed August 16, 2002, now U.S. Patent No. 6,765,006 B2, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AM2 cited on Form PTO 1449:

Document AM2 is in a foreign language. An English language translation of document AM2 is attached as document AR11.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey S. Lundgren  
Agent for Applicants  
Registration No. 51,978

Date: Aug. 20, 2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

				ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445		
				FIRST NAMED INVENTOR Upasani et al.			
				FILING DATE February 6, 2004	ART UNIT 1516		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM2	JP S51-8287	01/23/1976	Japan			X Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR	<u>11</u>	English language translation of Japanese Unexamined Patent Application No. JP S51-8287 published January 23, 1976, 7 pages. (Document AM2)				
	AS	<u>11</u>	Yamamoto, M., et al., "Quinazolin-2-ones from 3,4-dihydroquinazolin-2-ones," <i>Chem. Abstr.</i> 84:586, Abstract No. 180277m, American Chemical Society (1976)				
	AT	<u>11</u>	Supplementary Partial European Search Report for European Application No. EP99911063 filed on March 2, 1999				
EXAMINER					DATE CONSIDERED		
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							